Topic: Santaris Pharma A/S
Posted on 09/23/11 at 8:01am by Matthew Kennedy . Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announced today it has filed a patent infringement...
SPC3649 Successfully Inhibits miR-122, a microRNA Important for Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatitis C Virus in the Bloodstream in Chimpanzees Chronically Infected With the Hepatitis C Virus . A study published online in this week's Science shows that SPC3649 ...
Shire plc , the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare ...
Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer ...
Santaris Pharma announced today promising new findings on the in vitro and in vivo activity of a new class of microRNA-targeted therapeutic candidates developed with its proprietary Locked Nucleic Acid (LNA) technology platform. In both in vitro and in vivo models, including ...
A biopharmaceutical company in Denmark has designed a drug that blocks a specific microRNA strand involved in replicating hepatitis C, as well as in regulating cholesterol. The company, Santaris Pharma, is the first in the world to successfully test the technique in ...
